Preclinical Vaccine Combination Immunotherapy Platform

Q: Why is the combination of vaccines and ICIs superior to ICI monotherapy?

ICI monotherapy often fails in 'cold' tumors due to a lack of T cells. Our platform uses vaccines to generate these T cells first ('Prime'), ensuring the ICI has a target to act upon ('Release'), significantly expanding responder rates.

Q: Can you optimize the sequence of administration for these therapies?

Yes, timing is critical. Our platform specializes in sequential dosing studies to determine the most effective treatment window (e.g., Prime-then-Release) for your specific antigen and tumor model.

Q: What tumor models are best for evaluating combination synergy?

We primarily utilize syngeneic murine models with immunocompetent microenvironments, as well as humanized mouse models for testing human-specific immune checkpoint inhibitors.

Q: How do you measure 'Exhaustion Reversal' in your preclinical studies?

We use 18-parameter flow cytometry to monitor markers of dysfunction (PD-1, TIM-3) alongside markers of effector vigor (IFN-γ, Granzyme B) to confirm if combination therapy restores T-cell function.

Q: Is it possible to test multi-target combinations, such as Vaccine + ICI + Cytokine?

Yes, our platform is scalable and can design preclinical studies for triple or quadruple combinations to address multiple layers of tumor immune resistance.

Synergizing "Prime & Release" strategies to shatter tumor immune resistance. Creative Biolabs provides a robust preclinical development platform for combining therapeutic cancer vaccines with next-generation immune checkpoint inhibitors (ICIs).

Our platform follows the core logic of "Inducing de novo Immunity + Reversing TME Suppression." By integrating tumor-specific vaccines with tailored ICIs, we enable researchers to transform non-responsive "cold" tumors into reactive targets, maximizing the expansion and longevity of tumor-specific T cells.

Request Combination Study Plan

Overcoming Vaccine Resistance: The Synergistic Approach

As detailed in recent 2021 literature (Kim et al.), the combination of vaccines and immunotherapies represents the new frontier in oncology. Our platform addresses the primary causes of single-agent failure:

▶ Active T-cell Recruitment: Vaccines act as the "ignition" to induce and expand tumor-specific T-cell clones that are otherwise absent in immune-deserted tumors.
▶ Checkpoint Reversal: ICIs act as the "brake-release," ensuring that vaccine-induced effectors are not neutralized by PD-1, CTLA-4, or 2nd gen checkpoints (TIGIT, LAG-3) within the TME.
▶ Sustainable Immunological Memory: Dual therapy enhances the differentiation of central memory T cells, providing long-term protection against tumor recurrence and metastasis.

Integrated Preclinical Combination Solutions

We provide a fully integrated pipeline to evaluate and optimize the synergy between various vaccine formats and immunomodulators:

Rational Target Discovery

Bioinformatic identification of upregulated checkpoints (e.g., TIGIT, VISTA) in specific tumor models post-vaccination to guide the selection of the most synergistic ICI partner.

Sequential Dosing Optimization

Strategic evaluation of "Prime-then-Release" vs. "Simultaneous" schedules using preclinical models to determine the optimal window for immune infiltration and activation.

Synergy Quantification Assays

Utilizing high-parameter flow cytometry and ex vivo cytotoxicity assays to calculate synergy scores (e.g., Bliss independence) for vaccine-ICI combinations.

TME Mechanistic Dissection

Comprehensive profiling of TIL infiltration density, Treg/Effector ratios, and spatial cytokine distribution post-combination therapy to validate the "Prime & Release" logic.

Featured Preclinical Focus Areas

Our expertise targets the most promising combination strategies to solve existing R&D hurdles:

Cold Tumor Transformation

Utilizing multivalent vaccines to "warm up" non-immunogenic tumors, making them responsive to previously ineffective anti-PD-1/PD-L1 therapies.

Explore TME Mapping →

2nd Gen ICI Synergy

Evaluating the synergistic potential of vaccines combined with novel targets such as TIGIT, LAG-3, and B7-H3 for multi-layered immune activation.

View Novel Checkpoints →

Pharmacodynamic Synchronization

Optimization of administration routes and timing to ensure the vaccine-induced T-cell peak coincides with maximal checkpoint blockade.

Learn About PK/PD Logic →

Neoantigen-Combo Scaffolds

Integrating personalized neoantigen identification with standard combination protocols to evaluate precision vaccine effectiveness in preclinical models.

Get Precision Details →

Agile Preclinical Combination Development Workflow

Our systematic pipeline ensures the transition from mechanistic concept to a validated combination lead:

Step 1: Combination Rationale & Target Selection

Activities: Analyzing the baseline TME of your target tumor model. We utilize bioinformatic screening to identify which checkpoints are upregulated following initial vaccine priming, ensuring a rational pairing between the vaccine and the ICI candidate.

Outcome: A customized combination strategy tailored to specific immune evasion mechanisms.

Step 2: In Vitro Synergy Screening

Activities: Utilizing primary human or murine immune cell co-cultures to evaluate if the ICI enhances vaccine-primed T-cell proliferation and IFN-γ secretion. We measure the relief of T-cell exhaustion markers in vitro.

Outcome: Functional proof-of-concept and preliminary synergy scoring.

Step 3: Sequential Dosing & Synchronization Study

Activities: Pilot animal studies to test different administration schedules (e.g., vaccine priming 7 days before ICI release). We track the expansion kinetics of antigen-specific T cells via serial sampling to identify the optimal treatment window.

Outcome: Finalized dosing and scheduling protocol for pivotal efficacy studies.

Step 4: Syngeneic In Vivo Efficacy Analysis

Activities: Tracking tumor volume inhibition and survival rates in combination groups vs. single-agent controls. We monitor for long-term protective memory through tumor rechallenge experiments in cured animals.

Outcome: Statistical validation of antitumor potency and therapeutic superiority.

Step 5: Integrated TME & Mechanistic Profiling

Activities: Dissecting the "Post-Combo" TME using multiplex IF and high-parameter flow cytometry. We provide a final integrated report detailing TIL infiltration, Treg depletion, and exhaustion reversal signatures.

Outcome: A comprehensive preclinical package supporting lead candidate selection and IND-enabling studies.

Discuss Your Project Timeline

Core Combination Discovery Platforms

Our solutions are powered by industry-leading systems tailored for complex synergy dissection:

Combo-Score Analytics: A robust mathematical platform for quantifying the synergistic interaction between vaccines and immunomodulators. It utilizes high-throughput in vitro data to calculate the most potent combination ratios before entering animal studies.

Validated for 50+ ICI-Vaccine pairings
Bliss independence and Loewe additivity modeling
Real-time cytokine secretion kinetic tracking

Exhaustion-Reversal Profiler: Specialized flow cytometry suite designed to monitor the transition of vaccine-induced T cells from an "Exhausted" to a "Functional Effector" state following ICI administration.

18-parameter deep phenotyping (PD-1, TIM-3, LAG-3, Eomes, T-bet)
Cell polyfunctionality (IFN-γ/IL-2/TNF-α) mapping
Longitudinal memory T-cell precursor quantification

TME-Spatial Synergy Mapper: Modular platform combining multiplex IF and spatial transcriptomics to visualize the "Prime & Release" effect in situ. It helps confirm if the ICI successfully releases vaccine-induced cells trapped in the stroma.

In-situ visualization of CD8+, CD4+, and Treg spatial ratios
Quantification of "Immune Infiltrated" vs. "Immune Excluded" zones
Correlation of spatial metrics with overall tumor necrosis

Combo-Score

Exhaustion-Reversal

Spatial Synergy

Scientific Insight: Establishing a New Immunological Approach

Synergizing Vaccines and ICIs

Innovation: A comprehensive review in the International Journal of Molecular Sciences highlights the strategic necessity of combining therapeutic cancer vaccines with ICIs. The study establishes the "Combination Platform" as the gold standard for next-gen immunotherapy.

Research Highlights:

Core Mechanism: Vaccines trigger the "Prime" phase by inducing tumor-specific T cells, while ICIs drive the "Release" phase by overcoming TME-mediated exhaustion.
Overcoming Resistance: The study demonstrates how combination strategies bypass the limitations of single-therapy resistance, particularly in "cold" tumors.
Development Framework: Provides a theoretical framework for designing multivalent vaccines and optimizing their synergy with established checkpoints (PD-1/CTLA-4).

Action modes and resistance mechanisms of therapeutic cancer vaccines.

Fig.1 Modes of action and resistance mechanisms of therapeutic cancer vaccines.^1,2

Frequently Asked Questions

Q: Why is the combination of vaccines and ICIs superior to ICI monotherapy?

A: ICI monotherapy often fails in "cold" tumors because there are no T cells to release from suppression. Our combination platform uses vaccines to actively generate these T cells first. This ensures that the ICI has a relevant target population to act upon, significantly expanding the patient responder rate.

Q: Can you optimize the sequence of administration for these therapies?

A: Absolutely. Timing is critical. Our platform specializes in sequential dosing studies to determine if "Prime-then-Release" or simultaneous dosing is most effective for your specific antigen format and tumor model.

Q: What tumor models are best for evaluating combination synergy?

A: We primarily use syngeneic murine models (like B16-F10) which possess a complete, immunocompetent TME. We also offer humanized mouse models for testing human-specific ICIs alongside vaccine candidates.

Q: How do you measure 'Exhaustion Reversal' in your preclinical studies?

A: We utilize 18-parameter flow cytometry to track markers of T-cell dysfunction (PD-1, TIM-3) alongside markers of effector vigor (IFN-γ, Granzyme B, Ki67). A successful combination will show a shift toward high-effector/low-exhaustion signatures.

Q: Is it possible to test multi-target combinations, such as Vaccine + ICI + Cytokine?

A: Yes. Our platform is highly scalable. We can design preclinical studies to evaluate triple or quadruple combinations to target multiple layers of immune resistance, provided the rationale is supported by initial target discovery data.

Related Resources

References:
1. Kim, Chang-Gon, et al. "Combining cancer vaccines with immunotherapy: establishing a new immunological approach." International Journal of Molecular Sciences 22.15 (2021): 8035.
2. Distributed under Open Access License CC BY 4.0, without modification.